Effect of the ADAPT strategy on dormant CD133+ colon cancer stem cells (CSC) and molecular complete remission measured by peripheral blood mononuclear (PBMC) CD133 mRNA.
Edward H. Lin
Consultant or Advisory Role - Apomax Biolab
Stock Ownership - Apomax Biolab
Yu Xiazhen
No relevant relationships to disclose
Xi C He
No relevant relationships to disclose
Xifeng Wu
Consultant or Advisory Role - Apomax Biolab (U)
Yang Xie
No relevant relationships to disclose
Yanhong Deng
No relevant relationships to disclose
Guang Yang
No relevant relationships to disclose
Qiang Tian
Consultant or Advisory Role - Apomax Biolab
Lingheng Li
No relevant relationships to disclose